全球癌症標靶阿爾法療法市場

本研究報告概況了癌症治療的標靶α療法的全球市場並分析了市場趨勢。

基準年資料包括2024年全球收益（百萬美元）、2025年估計資料以及到2030年的估計和預測年複合成長率。

調查範圍

本報告概述並分析了全球癌症標靶α療法（TAT）市場。報告包含基準年2024年的全球收益（百萬美元）以及預測期2025年至2030年的估值。市場按癌症類型細分。

本報告重點關注影響市場和供應商格局的趨勢和挑戰。報告分析了各公司的環境、社會和管治（ESG）發展情況，並探討了與市場相關的新興技術。此外，報告還包含競爭和產品線分析。公司簡介部分涵蓋關鍵財務資訊、產品系列以及行業領導者的最新發展動態。

報告內容

• 全球癌症標靶α療法（TAT）市場概況及分析
• 全球市場趨勢分析，包括2022年至2024年的歷史市場收益資料、2025年的估計和預測以及2030年的年複合成長率預測
• 本報告估計了全球市場的當前市場規模和收益預測，並提供了依癌症類型和地區分類的市場佔有率分析。
• 有關市場動態、技術進步、法規、預測和宏觀經濟變數影響的事實和資料
• 波特五力模型的見解、新興趨勢和技術資訊、最新發展以及產品平臺分析
• 永續性趨勢和 ESG 發展概述，重點在於消費者態度、ESG 風險評估和主要企業的實踐
• 專利分析，包括主要授權和公佈的專利
• 產業結構分析，包括公司市場佔有率和排名、策略舉措、併購活動和創業融資前景
• 主要企業簡介

目錄

第1章 執行摘要

第2章 市場概況

• 概述
• 宏觀經濟因素分析
• 人口因素
• 地緣政治因素
• 美國關稅法的影響
• 波特五力分析
• 價值鏈分析

第3章 市場動態

• 市場動態
• 市場促進因素
• 癌症發生率上升
• 精準醫療的需求
• 腫瘤學中未滿足的治療需求
• 加強策略性舉措
• 市場限制
• 供應鍊和製造問題
• 監管障礙
• 市場挑戰
• 劑量計算
• 後座力效應
• 市場機會
• 新目標
• 聯合治療

第4章 監理現狀

• 監管情景
• 美國
• 歐洲聯盟
• 日本

第5章 新興科技與發展

• 新興技術
• 藥物發行策略的進展
• 治療診斷學
• 管道分析
• 關鍵要點

第6章 市場區隔分析

• 概述
• 細分市場
• 依癌症類型進行市場分析
• 關鍵要點
• 攝護腺癌
• 神經內分泌腫瘤
• 其他
• 依地區細分
• 區域市場分析
• 關鍵要點
• 北美洲
• 歐洲
• 亞太地區
• 其他地區

第7章 競爭訊息

• 關鍵要點
• 市場分析
• 策略舉措
• 合約、合作和夥伴關係
• 獲得
• 其他策略

第8章 癌症治療市場中標靶α療法的永續性：ESG 視角

第9章 附錄

• 調查方法
• 來源
• 簡稱
• 公司簡介
• ACTINIUM PHARMACEUTICALS INC.
• ADVANCELL PTY LTD.
• BAYER AG
• CONVERGENT THERAPEUTICS INC.
• FUSION PHARM
• NOVARTIS AG
• ORANO MED
• PERSPECTIVE THERAPEUTICS
• RADIOMEDIX INC.
• RAYZEBIO INC.
• 市場上的新興新Start-Ups

This report provides an overview of the global market for targeted alpha therapies for cancer and analyzes market trends. It includes global revenue ($ millions) for the base year data 2024 and estimated data for 2025, forecasted CAGRs through 2030.

Report Scope

The report provides an overview of the global market for targeted alpha therapies (TAT) for cancer and analyzes market trends. It includes global revenue ($ million) for the base year data 2024 and estimated data for the forecast period 2025 through 2030. The market is segmented based on cancer type.

The report focuses on trends and challenges that affect the market and vendor landscape. It analyzes corporate environmental, social and governance (ESG) developments and discusses emerging technologies related to the market. The report includes an analysis of the competitive landscape and pipeline analysis. A section dedicated to company profiles addresses key financials, product portfolios and recent developments involving industry leaders.

Report Includes

• Overview and an analysis of the global market for targeted alpha therapies (TAT) for cancer treatment
• Analyses of the global market trends, with historical market revenue data from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
• Estimates of the current market size and revenue prospects of the global market, accompanied by a market share analysis by cancer type and region
• Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables
• Insights derived from Porter's Five Forces model, and information on emerging trends and technologies, latest developments, and product pipeline analysis
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• A relevant patent analysis, featuring key granted and published patents
• Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
• Profiles of the leading companies

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Overview
• Current Market Scenario
• Segmental Analysis
• Emerging Technologies
• Conclusion

Chapter 2 Market Overview

• Overview
• Macroeconomic Factors Analysis
• Demographic Factors
• Geopolitical Factors
• Impact of the U.S. Tariff Laws
• Porter's Five Forces Analysis
• Potential of New Entrants: Moderate to Low
• Bargaining Power of Suppliers: High
• Bargaining Power of Buyers: Moderate
• Threat of Substitute Products or Services: Moderate
• Industry Competition: Low
• Value Chain Analysis

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Increased Prevalence of Cancer
• Demand for Precision Medicine
• Unmet Treatment Need in Oncology
• Increased Strategic Initiatives
• Market Restraints
• Supply Chain and Manufacturing Issues
• Regulatory Hurdles
• Market Challenges
• Dosimetry Calculations
• Recoil Effect
• Market Opportunities
• New Targets
• Combination Therapies

Chapter 4 Regulatory Landscape

• Regulatory Scenario
• The U.S.
• European Union
• Japan

Chapter 5 Emerging Technologiesand Developments

• Emerging Technologies
• Advances in Drug Delivery Strategies
• Theranostics
• Pipeline Analysis
• Key Takeaways

Chapter 6 Market Segmentation Analysis

• Overview
• Segmentation Breakdown
• Market Analysis by Cancer Type
• Key Takeaways
• Prostate Cancer
• Neuroendocrine Tumors
• Other Cancers
• Geographic Breakdown
• Market Analysis by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Key Takeaways
• Market Analysis
• Strategic Initiatives
• Agreements, Collaborations and Partnerships
• Acquisitions
• Other Strategies

Chapter 8 Sustainability in Targeted Alpha Therapies for Cancer Treatment Market: An ESG Perspective

• Introduction to ESG
• Sustainability in the Targeted Alpha Therapies Industry
• ESG Performance Analysis
• Environmental Initiatives
• Social Initiatives
• Governance Initiatives
• ESG Risk Ratings
• Conclusion

Chapter 9 Appendix

• Research Methodology
• Sources
• Abbreviations
• Company Profiles
• ACTINIUM PHARMACEUTICALS INC.
• ADVANCELL PTY LTD.
• BAYER AG
• CONVERGENT THERAPEUTICS INC.
• FUSION PHARM
• NOVARTIS AG
• ORANO MED
• PERSPECTIVE THERAPEUTICS
• RADIOMEDIX INC.
• RAYZEBIO INC.
• Emerging Startups in the Market

List of Tables

• Summary Table : Global Market for Targeted Alpha Therapies for Cancer Treatment, by Cancer Type, Through 2030
• Table 1 : Common Characteristics, Production Methods, Delivery Strategies and Clinical Applications of Alpha-Emitters
• Table 2 : Global Cancer Incidence and Mortality Rates, by the WHO Region, 2022
• Table 3 : Strategic Initiatives in Targeted Alpha Therapy Market, 2023-2025
• Table 4 : List of Selected Targeted Alpha Therapies, July 2025
• Table 5 : Global Market for Targeted Alpha Therapies for Cancer Treatment, by Cancer Type, Through 2030
• Table 6 : Agreements, Collaborations and Partnerships in the Targeted Alpha Therapies for Cancer Treatment Market, 2021-2025
• Table 7 : Acquisitions in the Targeted Alpha Therapies for Cancer Treatment Market, 2021-2024
• Table 8 : Other Strategic Initiatives in the Targeted Alpha Therapies for Cancer Treatment Market, 2022-2025
• Table 9 : ESG Risk Rankings for Targeted Alpha Therapies Companies, 2025*
• Table 10 : Information Sources in this Report
• Table 11 : Abbreviations
• Table 12 : Actinium Pharmaceuticals Inc.: Company Snapshot
• Table 13 : Actinium Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
• Table 14 : Actinium Pharmaceuticals Inc.: Product Pipeline
• Table 15 : Actinium Pharmaceuticals Inc.: News/Key Developments, 2023-2025
• Table 16 : AdvanCell Pty Ltd.: Company Snapshot
• Table 17 : AdvanCell Pty Ltd.: Product Pipeline
• Table 18 : AdvanCell Pty Ltd.: News/Key Developments, 2023-2025
• Table 19 : Bayer AG: Company Snapshot
• Table 20 : Bayer AG: Financial Performance, FY 2023 and 2024
• Table 21 : Bayer AG: Product Portfolio
• Table 22 : Bayer AG: News/Key Developments, 2021-2025
• Table 23 : Convergent Therapeutics Inc.: Company Snapshot
• Table 24 : Convergent Therapeutics Inc.: Product Pipeline
• Table 25 : Convergent Therapeutics Inc.: News/Key Developments, 2021-2024
• Table 26 : Fusion Pharma: Company Snapshot
• Table 27 : Fusion Pharma: Product Pipeline
• Table 28 : Fusion Pharma: News/Key Developments, 2024
• Table 29 : Novartis AG: Company Snapshot
• Table 30 : Novartis AG: Financial Performance, FY 2023 and 2024
• Table 31 : Novartis AG: Product Pipeline
• Table 32 : Novartis AG: News/Key Developments, 2024
• Table 33 : Orano Med: Company Snapshot
• Table 34 : Orano Med: Product Pipeline
• Table 35 : Orano Med: News/Key Developments, 2023-2025
• Table 36 : Perspective Therapeutics: Company Snapshot
• Table 37 : Perspective Therapeutics: Financial Performance, FY 2023 and 2024
• Table 38 : Perspective Therapeutics: Product Pipeline
• Table 39 : Perspective Therapeutics: News/Key Developments, 2024
• Table 40 : RadioMedix Inc.: Company Snapshot
• Table 41 : RadioMedix Inc.: Product Pipeline
• Table 42 : RadioMedix Inc.: News/Key Developments, 2022-2025
• Table 43 : RayzeBio Inc.: Company Snapshot
• Table 44 : RayzeBio Inc.: Product Pipeline
• Table 45 : RayzeBio Inc: News/Key Developments, 2024
• Table 46 : Other Emerging Startups in the Targeted Alpha Therapies for Oncology Market

List of Figures

• Summary Figure : Global Market Shares of Targeted Alpha Therapies for Cancer Treatment, by Cancer Type, 2030
• Figure 1 : Porter's Five Forces Analysis of the Targeted Alpha Therapies for Cancer Treatment Market
• Figure 2 : Targeted Alpha Therapies for Cancer: Value Chain Analysis
• Figure 3 : Market Dynamics of Targeted Alpha Therapies for Cancer Treatment
• Figure 4 : Cancer Incidence in the U.S., 2010-2022
• Figure 5 : Clinical Trials Shares on Targeted Alpha Therapies, by Phase, as of July 2025
• Figure 6 : Clinical Trials Shares on Targeted Alpha Therapies, by Study Type, July 2025
• Figure 7 : Clinical Trials Shares on Targeted Alpha Therapies, by Study Status, as of July 2025
• Figure 8 : Clinical Trials Shares on Targeted Alpha Therapies, by Radioisotope, as of July 2025
• Figure 9 : Bayer AG: Revenue Shares, by Business Unit, FY 2024
• Figure 10 : Bayer AG: Revenue Shares, by Country/Region, FY 2024
• Figure 11 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
• Figure 12 : Novartis AG: Revenue Shares, by Country/Region, FY 2024